Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (14 ops.)
Latest filing published 20 Apr 2026 for Ultragenyx Pharmaceutical Inc.. Read the official filing
Filing timeline
BuySaleEmil d. Kakkis
Insider track record
Disclosed buys
0
Disclosed sells
14
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Emil d. Kakkis: trading record in brief
Emil d. Kakkis is a declared insider of Ultragenyx Pharmaceutical Inc. (chief executive), with filings sourced from SEC (Form 4). Between 30 December 2015 and 16 April 2026, the trades on record add up to 24 filings.
Sales make up the whole of the open-market record (14 sales, €8.5M). The totals exclude 7 filings filed without an amount. Besides market trades, the filings include 8 share grants and 1 option exercise.
The record was last updated on 20 April 2026 with a share grant in Ultragenyx Pharmaceutical Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Emil d. Kakkis
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations24 total
76,745 shares0Common StockSEC:0001193125-26-164308:0
71,177 shares0Common StockSEC:0001193125-26-089278:0
43,268 shares0Common StockSEC:0000950170-25-032779:0
11,727 shares@ US$42.233.8% of flowCommon StockSEC:0000950170-24-141485:0
20,000 shares0Common StockSEC:0000950170-24-135521:0
20,000 shares@ US$55.858.1% of flowCommon StockSEC:0000950170-24-103811:0
20,000 shares@ US$50.177.4% of flowCommon StockSEC:0000950170-24-092608:0
38,428 shares0Common StockSEC:0000950170-24-026625:0
30,000 shares@ US$45.0010.1% of flowCommon StockSEC:0001209191-24-002989:0
30,000 shares@ US$47.8710.4% of flowCommon StockSEC:0001209191-24-000071:0
47,853 shares@ US$6.862.5% of flowCommon StockSEC:0001209191-23-053351:0
8,716 shares0Common StockSEC:0001209191-23-016041:0
19,582 shares@ US$45.576.7% of flowCommon StockSEC:0001209191-23-000276:0
12,162 shares@ US$67.370.030% mcap11.5% of flowCommon StockSEC:0001209191-22-015799:0
853 shares@ US$81.000.6% of flowCommon StockSEC:0001209191-21-060749:0
852 shares@ US$115.710.8% of flowCommon StockSEC:0001209191-21-031383:0
30,000 shares@ US$107.8027.8% of flowCommon StockSEC:0001209191-21-030211:0
2,837 sharesCommon StockSEC:0001562180-16-001158:0
5,465 sharesCommon StockSEC:0001562180-16-001158:1
3,600 sharesCommon StockSEC:0001562180-16-001158:2
2,600 sharesCommon StockSEC:0001562180-16-001158:3
2,191 sharesCommon StockSEC:0001562180-16-001158:4
2,702 sharesCommon StockSEC:0001562180-16-001158:5
605 sharesCommon StockSEC:0001562180-16-001158:6
24 of 24 declarations
